Author

Seyi Abidoye

Observed name: Seyi abidoye

Institutions: Mayo Clinic, Mayo Clinic Hospital, Mayo Clinic Comprehensive Cancer Center (Arizona)

Observed institutions: Mayo Clinic, Mayo Clinic in Arizona, Mayo Clinic Hospital, Mayo Clinic Comprehensive Cancer Center (Arizona)

ORCID: 0000-0002-5666-6085

Observed ORCID: 0000-0002-5666-6085

OpenAlex ID: A5116836734

Real World Outcomes and Predictive Factors of Pirtobrutinib in Mantle Cell Lymphoma After Failure of Covalent Bruton Tyrosine Kinase Inhibitors

2026 · Tycel Phillips, Paolo Lopedote, et al. · Research Square

Concordance of Circulating Tumor DNA, Primary and Metastatic Tissue DNA, and Immunohistochemistry in Gastroesophageal Carcinoma

2026 · Fares Jamal, Oudai Sahwan, et al. · JCO Precision Oncology

Biomarker-Driven Precision Oncology in Advanced Gastroesophageal Adenocarcinoma: Current Standards and Future Directions

2026 · Fares Jamal, Abdullah Alsulaiman, et al. · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics

Multi-center real world analysis of treatment outcomes of non-COVALENT btki, pirtobrutinib, in patients with COVALENT btki relapsed/refracdtory Mantle Cell Lymphoma

2025 · Paolo Lopedote, Adrienne Nedved, et al. · Blood

CLO25-095: Baseline Genomic Alterations as Predictors of Response to Anti-HER2 Therapy in HER2-Amplified Advanced Colorectal Cancer (aCRC)

2025 · Celine Hoyek, Angelo Pirozzi, et al. · Journal of the National Comprehensive Cancer Network

Works count: 5

Citation count:

H-index:

I10-index: